Skip to main contentAI and Advanced
/
ORTINGLOBE · BSEMarket ticker unavailable · configure an authorised index feed
OR
BSE · Equity shares · Biotechnology & Drugs-0.49 · -2.86%
Ortin Global ORTINGLOBE
NSE:INR 16.62
BSE:INR 15.45
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for ORTINGLOBE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 17.11
Day rangeINR 16.62 — INR 17.58
52-week rangeINR 10.66 — INR 21.3
Volume16,468
Market cap12.56
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)0.1
Net Income (INR Cr)-0.74
EPS-0.91
Research path: Interpret Ortin Global's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ORTINGLOBEOrtin Global1d · INR · BSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 4.65 | 3.78 | 6.66 |
| Cash Equivalents | 0.61 | 0.37 | 2.34 |
| Long Term Debt | 1.01 | 0.25 | 1.8 |
| Common Stock Total | 8.13 | 8.13 | 8.13 |
| Other Current Assets Total | 3.03 | 2.69 | 2.19 |
| Total Assets | 4.65 | 3.78 | 6.66 |
| Current Portof LT Debt/Capital Leases | 0 | 0 | 0 |
| Total Equity | 1.24 | 1.98 | 2.82 |
| Long Term Investments | 0.76 | 0.37 | 0.23 |
| Retained Earnings(Accumulated Deficit) | -6.89 | -6.15 | -5.31 |
| Total Common Shares Outstanding | 0.81 | 0.81 | 0.81 |
| Tangible Book Valueper Share Common Eq | 1.52 | 2.43 | 3.47 |
| Total Liabilities | 3.41 | 1.8 | 3.84 |
| Total Debt | 1.01 | 0.25 | 1.8 |
| Cashand Short Term Investments | 0.61 | 0.37 | 2.34 |
| Total Receivables Net | 0.2 | 0.26 | 1.77 |
| Accounts Receivable-Trade Net | 0.2 | 0.26 | 1.77 |
| Property/Plant/Equipment Total-Net | 0.01 | 0 | 0.01 |
| Total Current Liabilities | 2.41 | 1.55 | 2.04 |
| Total Inventory | 0 | 0.02 | 0.05 |
| Accounts Payable | 0.04 | 0.04 | 0.08 |
| Other Currentliabilities Total | 2.37 | 1.51 | 1.96 |
| Total Long Term Debt | 1.01 | 0.25 | 1.8 |
| Other Long Term Assets Total | 0.05 | 0.07 | 0.07 |
| Total Current Assets | 3.84 | 3.34 | 6.34 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
| Other Liabilities Total | Not available | Not available | 0 |
| Deferred Income Tax | Not available | Not available | 0 |
| Capital Lease Obligations | Not available | Not available | 0 |
Fundamentals
Valuation and ratios
Valuation
Price to Sale Ratio125.60
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk64.09
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,938 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,371.1 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,981.75 | 1.69 L | 72.73 | — |
| Cipla | INR 1,410.35 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,120.75 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 1.23%
- FII
- 1.80%
- Other
- 96.97%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Ortin Global Ltd Open Offer: Rarever Financial Advisors Submits Corrigendum - WhalesbookMarket news · 5 Jun 2026, 1:54 pm
Ortin Global Ltd Open Offer: Rarever Financial Advisors Submits Corrigendum Whalesbook
Ortin Global open offer price fair, says committee - scanx.tradeMarket news · 4 Jun 2026, 1:45 am
Ortin Global open offer price fair, says committee scanx.trade
Ortin Global Independent Directors deem Parveen Satija's open offer fair - WhalesbookMarket news · 3 Jun 2026, 8:23 pm
Ortin Global Independent Directors deem Parveen Satija's open offer fair Whalesbook
Ortin Global reports standalone net loss of Rs 0.01 crore in the March 2026 quarter - Business StandardMarket news · 1 Jun 2026, 10:41 am
Ortin Global reports standalone net loss of Rs 0.01 crore in the March 2026 quarter Business Standard
Abhinav Leasing & Finance reports standalone net loss of Rs 0.32 crore in the March 2026 quarter - Business StandardMarket news · 1 Jun 2026, 10:41 am
Abhinav Leasing & Finance reports standalone net loss of Rs 0.32 crore in the March 2026 quarter Business Standard
Virat Leasing standalone net profit declines 8.33% in the March 2026 quarter - Business StandardMarket news · 1 Jun 2026, 9:38 am
Virat Leasing standalone net profit declines 8.33% in the March 2026 quarter Business Standard
Corporate actions
Events
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- annual General MeetingEGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Ortin Global
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Ortin Global Limited is an India-based company, which is engaged in the manufacturing and trading of pharmaceuticals, drugs and intermediates, to manufacture, sell or export all types of medicines, including ayurvedic, homeopathic, Unani, biochemical, nature cure and others. The Company is also engaged in the real estate business.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ORTINGLOBE
- BSE Code
- 539287
Questions
Stock FAQ
What is the symbol and ISIN of Ortin Global?
Ortin Global has the symbol ORTINGLOBE and ISIN - INE749B01020.
What is the current price of Ortin Global?
Ortin Global is currently trading at INR 16.62.
What are the year high and year low of Ortin Global?
Ortin Global has a year high of INR 21.30 and a year low of INR 10.66.
What is the market capitalization of Ortin Global?
Ortin Global has a market capitalization of INR 12.56 crore.
What is the P/E ratio of Ortin Global?
Ortin Global has a P/E ratio of NA.
What is the dividend yield of Ortin Global?
Ortin Global has a dividend yield of NA.
How is the financial performance of Ortin Global based on revenue, net income, and EPS?
Ortin Global has revenue of INR 0.10 crore, net income of INR -0.74 crore, and EPS of NA.
What is the book value of Ortin Global?
Ortin Global has a book value of NA.
What is the debt-to-equity ratio of Ortin Global?
Ortin Global has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Ortin Global?
Ortin Global has a price-to-book ratio of NA and a price-to-sales ratio of 125.60.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.